IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

(2020) Masatoshi Kudo   Cancers

The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes

(2020) Floris Dammeijer et al.   CANCER CELL

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

(2020) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?

(2019) Masayuki Takeda et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

(2019) Martin Reck et al.   Lancet Respiratory Medicine

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

(2019) Howard West et al.   LANCET ONCOLOGY

Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib

(2019) Yuxin Mu et al.   Targeted Oncology

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR , ALK , ROS1 , KRAS or BRAF

(2019) Xibin Zhuang et al.   Cancer Medicine

Immune Checkpoint Blockade – How Does It Work in Brain Metastases?

(2019) Mihaela Lorger et al.   Frontiers in Molecular Neuroscience

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tissue-Specific Immunoregulation: A Call for Better Understanding of the “Immunostat” in the Context of Cancer

(2018) William Pao et al.   Cancer Discovery

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

(2018) Bharathi Vennapusa et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study

(2018) Leora Horn et al.   EUROPEAN JOURNAL OF CANCER

Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis

(2017) Chee Khoon Lee et al.   Journal of Thoracic Oncology

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics

(2017) Priti S. Hegde et al.   SEMINARS IN CANCER BIOLOGY

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

(2017) Paul C. Tumeh et al.   Cancer Immunology Research

Estimating Survival in Patients With Lung Cancer and Brain Metastases

(2017) Paul W. Sperduto et al.   JAMA Oncology

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

(2016) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma

(2016) A. Ilhan-Mutlu et al.   MOLECULAR CANCER THERAPEUTICS

Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer

(2016) Ming-Szu Hung et al.   Oncology Letters

Prognostic effect of liver metastasis in lung cancer patients with distant metastasis

(2016) Yijiu Ren et al.   Oncotarget

Metastatic sites and survival in lung cancer

(2014) M. Riihimäki et al.   LUNG CANCER

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Incidence of brain metastasis at initial presentation of lung cancer

(2014) J. Lee Villano et al.   NEURO-ONCOLOGY

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

(2013) Laurence Zitvogel et al.   IMMUNITY

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo

(2011) A. M. Paterson et al.   JOURNAL OF IMMUNOLOGY

The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo

(2011) J. Yang et al.   JOURNAL OF IMMUNOLOGY

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

(2010) J.-J. Park et al.   BLOOD

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER